Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-17

Harrow (HROW)

CEO Mark Baum was paid $23,606,274 in fiscal year 2025, ↑ up 1637.7% from fiscal year 2024, the 99th percentile of its disclosed peer group (SEC filing 0001493152-26-018912 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$23,606,274 ↑
Mark Baum total, FY2025
99th
CEO pay percentile vs peers
263:1
CEO-to-median pay ratio
88.29%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

HROW's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Baum$754,910$0$22,294,873$0$542,491$0$14,000$23,606,274
Chief Executive Officer and Chairman of the Board of Directors
Andrew Boll505,259010,169,9240258,258014,00010,947,441
President, Chief Financial Officer and Corporate Secretary
Amir Shojaei441,34600670,569225,00005,7121,342,627
Chief Scientific Officer
Francis Mullery129,808001,054,62453,260001,237,692
President and Chief Executive Officer, ImprimisRx Division
John Saharek475,614000237,807014,000727,421
Former President and Chief Executive Officer, ImprimisRx Division

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Mark Baum$23,606,274$1,358,490$15,256,463↑ +22,247,784
Andrew Boll10,947,441849,2017,130,409↑ +10,098,240
Amir Shojaei1,342,627———
Francis Mullery1,237,692———
John Saharek727,421743,4675,815,154↓ −16,046

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Harrow's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper HROW reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against HROW
5 companies name HROW as a compensation peer

The list of companies that name HROW as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Adrienne L. GravesIndependent Director$308,764
Lauren P. SilvernailIndependent Director$307,514
Martin A. MakaryFormer director (through FY2025)—
Perry J. SternbergLead Independent Director$327,514
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mark L. BaumDirector2026-05-14A10,000$30$302,000CommonForm 4 ↗
Andrew BollPRESIDENT AND CFO2026-05-14A3,50030104,650CommonForm 4 ↗
Amir ShojaeiCHIEF SCIENTIFIC OFFICER2026-05-15A10,00000Derivative, Class A CommonForm 4 ↗
Adrienne L. GravesDirector2026-05-18A1,0003131,070CommonForm 4 ↗
Lauren P. SilvernailDirector2026-05-18A1,0003131,000CommonForm 4 ↗
Adrienne L. GravesDirector2026-06-18A5,24800Derivative, Class A CommonForm 4 ↗
Lauren P. SilvernailDirector2026-06-18A5,24800Derivative, Class A CommonForm 4 ↗
Perry J. SternbergDirector2026-06-18A5,24800Derivative, Class A CommonForm 4 ↗
Amir ShojaeiCHIEF SCIENTIFIC OFFICER2026-08-14D11,25036404,550Derivative, Class A CommonForm 4 ↗
Amir ShojaeiCHIEF SCIENTIFIC OFFICER2026-08-14D11,25040450,000CommonForm 4 ↗
Amir ShojaeiCHIEF SCIENTIFIC OFFICER2026-08-14A11,25036404,550CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Andrew BollPSU2025-07-01———405,750$10,169,924
Mark BaumPSU2025-07-01———889,50022,294,873
Amir ShojaeiOPTION2025-01-06——30,000—670,569
Francis MulleryOPTION2025-09-30——33,000—1,054,624
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Andrew Boll$0$10,169,924$0100.0%
Mark Baum022,294,8730100.0%
Amir Shojaei00670,5690.0%
Francis Mullery001,054,6240.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Andrew BollPSU258,258—$464,864
Francis MulleryOption33,00048.18—
Amir ShojaeiOption30,00035.96—
Amir ShojaeiPSU225,000—405,000
Francis MulleryPSU52,260—94,068
Mark BaumPSU889,500—1,601,100
John SaharekPSU237,807—428,053
Mark BaumPSU542,491—976,484
Andrew BollPSU405,750—730,350
05

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee believes that executive compensation should be directly linked both to continuous improvements in corporate performance (pay for performance) and the achievement of objectives that are expected to increase stockholder value.

CEO STI target (% of salary)70%
CEO LTI target (% of salary)—
Independent consultantMercer, Inc.
Clawback policyTrue
Anti-hedgingFalse
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1818,065,8562,395,240502,67988.29%Passed
20252025-06-1822,496,427971,206448,77795.86%Passed
20242024-06-1414,877,1981,709,038133,73689.7%Passed
20232023-06-2119,733,427849,799288,21395.87%Passed
20222022-06-0913,569,789284,58040,15797.95%Passed
20212021-06-0314,781,072600,632583,32796.1%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1888.29%a
20252025-06-1895.86%b
20242024-06-1489.7%c

a. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.

b. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.

c. Approved under the standard stated in the filing — “Because directors are elected by a plurality of the votes cast, abstentions and broker non-votes will not be counted in determining which nominees receive the largest number of votes cast and, therefore, will have no effect on the outcome of the vote on this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)263 : 1
CEO total compensation$23,606,274
Median employee compensation$89,719
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Perry J. SternbergIndependent · Lead Independent Director · Audit · Compensation · Nominating/Governance$102,500$225,014$0$0$0$327,514
Adrienne L. GravesIndependent · Audit · Compensation (Chair) · Nominating/Governance (Chair)83,750225,014000308,764
Lauren P. SilvernailIndependent · Audit (Chair) · Compensation · Nominating/Governance82,500225,014000307,514
Martin A. MakaryIndependent · Audit · Compensation · Nominating and Corporate Governance · Not standing for re-election · Departed during FY000000
Mark L. BaumEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$268,750
Equity awards (grant-date value)$675,042
All other compensation$0
Total cost of the board$943,792

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Harrow names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Harrow.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Harrow2025Mark Baum$754,910$22,294,873$0$542,491$23,606,274
2Mirum Pharmaceuticals2025Christopher Peetz755,0003,683,9044,931,3201,057,00010,441,224
3ANI Pharmaceuticals2025Nikhil Lalwani837,4097,848,71101,572,50010,278,620
4Arrowhead Pharmaceuticals2025Christopher Anzalone981,0466,810,29201,236,0009,029,861
5Dynavax Technologies2024Ryan Spencer835,0014,902,1501,824,299641,9078,210,775
6Ardelyx2025Michael Raab797,0002,953,7243,413,948627,6387,796,171
7STAAR Surgical2025Stephen Farrell580,0006,836,000007,522,385
8Tarsus Pharmaceuticals2025Bobak Azamian726,3332,648,2842,651,487555,7006,617,979
9Eyepoint Pharmaceuticals2025Jay Duker696,2511,610,7002,604,113632,7005,568,352
10Agios Pharmaceuticals2025Brian Goff846,8641,291,6802,627,252592,8045,370,389
11RxSight2025Ron Kurtz630,62503,816,530202,9354,650,661
12Heron Therapeutics2025Craig Collard689,431946,2541,352,917517,1893,516,291
13Ironwood Pharmaceuticals2025Thomas McCourt867,568411,6960650,6761,948,390

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Harrow100%not disclosedNoMercer, Inc.
Agios Pharmaceuticals100%Option 40 · PSU 40 · RSU 20NoAon
ANI Pharmaceuticals185%RSU 75 · PSU 25Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences IndexPearl Meyer & Partners, LLC
Ardelyx105%Options 50 · RSU 50not disclosedPearl Meyer
Arrowhead Pharmaceuticals125%PSU 70 · RSU 30not disclosedCompensia
Dynavax Technologies102.5%Options 34 · RSU 33 · PSU 33Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology IndexAlpine
Eyepoint Pharmaceuticalsnot disclosednot disclosednot disclosedAon
Heron Therapeuticsnot disclosedOption 66.67 · RSU 33.33not disclosedCompensia, Inc.
Ironwood Pharmaceuticals100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Mirum Pharmaceuticals200%Option 47.2 · PSU 17.6 · RSU 17.6NoAlpine Rewards
RxSight32.18%Option 100not disclosedAon
STAAR Surgical135%RSU 50 · PSU 50NoSemler Brossy
Tarsus Pharmaceuticals108%Options 50 · RSU 50NoPay Governance

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Harrow in fiscal 2025?
As disclosed, Mark Baum (Chief Executive Officer and Chairman of the Board of Directors) was the highest-paid executive at Harrow in fiscal 2025, with total compensation of $23,606,274.
How does Harrow's chief executive pay compare to its disclosed peer group?
As disclosed, Mark Baum's total compensation ranked at the 99th percentile of Harrow's disclosed peer group.
What is Harrow's CEO-to-median employee pay ratio?
As disclosed, Harrow's CEO-to-median employee pay ratio was 263:1.
How did shareholders vote on Harrow's executive compensation?
As disclosed, 88.29% of shareholders supported Harrow's executive compensation in the latest say-on-pay vote.
How much does Harrow spend in total on board compensation for fiscal 2025?
As disclosed, Harrow reported total board compensation of $943,792 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mark BaumDEF 14A2026-04-240001493152-26-018912Section “Summary Compensation Table”. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999
2Section 01, Andrew BollDEF 14A2026-04-240001493152-26-018912Section “Summary Compensation Table”. As printed: 10,947,441. Filing ↗machine: t87 · r4 · c26 · span 390346–390356
3Section 01, Amir ShojaeiDEF 14A2026-04-240001493152-26-018912Section “Summary Compensation Table”. As printed: 1,342,627. Filing ↗machine: t87 · r8 · c26 · span 394722–394731
4Section 01, Francis MulleryDEF 14A2026-04-240001493152-26-018912Section “Summary Compensation Table”. As printed: 1,237,692. Filing ↗machine: t87 · r7 · c26 · span 393586–393595
5Section 01, John SaharekDEF 14A2026-04-240001493152-26-018912Section “Summary Compensation Table”. As printed: 727,421. Filing ↗machine: t87 · r9 · c26 · span 395905–395912
6Section 03, Andrew Boll PSUDEF 14A1900-01-010001493152-26-018912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 389758–389768
7Section 03, Mark Baum PSUDEF 14A1900-01-010001493152-26-018912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 386237–386247
8Section 03, Amir Shojaei OPTIONDEF 14A1900-01-010001493152-26-018912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 394313–394320
9Section 03, Francis Mullery OPTIONDEF 14A1900-01-010001493152-26-018912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 393180–393189
10Section 07, pay ratioDEF 14A2026-04-240001493152-26-018912Section “CEO Pay Ratio”. As printed: 263 : 1. Filing ↗machine: t117 · r1 · c3 · span 548949–548955
11Section 08, Perry J. SternbergDEF 14A2026-04-240001493152-26-018912Section “Director Compensation”. As printed: 327,514. Filing ↗machine: t48 · r3 · c11 · span 243128–243135
12Section 08, Adrienne L. GravesDEF 14A2026-04-240001493152-26-018912Section “Director Compensation”. As printed: 308,764. Filing ↗machine: t48 · r1 · c11 · span 241699–241706
13Section 08, Lauren P. SilvernailDEF 14A2026-04-240001493152-26-018912Section “Director Compensation”. As printed: 307,514. Filing ↗machine: t48 · r2 · c11 · span 242440–242447
14Section 08, Martin A. MakaryDEF 14A2026-04-240001493152-26-018912Section “Director Compensation”. As printed: 0. Filing ↗machine: t48 · r4 · c15 · span 243931–243932
15Section 08, Mark L. BaumDEF 14A2026-04-240001493152-26-018912Section “Director Compensation”. As printed: 0. Filing ↗
16Section 02, Mark L. Baum 2026-05-14Form 42026-05-150001493152-26-023321Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Andrew Boll 2026-05-14Form 42026-05-150001493152-26-023319Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Amir Shojaei 2026-05-15Form 42026-05-180001493152-26-024208Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Adrienne L. Graves 2026-05-18Form 42026-05-190001493152-26-024342Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Lauren P. Silvernail 2026-05-18Form 42026-05-190001493152-26-024341Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Adrienne L. Graves 2026-06-18Form 42026-06-220001493152-26-029657Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Lauren P. Silvernail 2026-06-18Form 42026-06-220001493152-26-029658Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Perry J. Sternberg 2026-06-18Form 42026-06-220001493152-26-029659Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Amir Shojaei 2026-08-14Form 42026-08-170001493152-26-038807Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Amir Shojaei 2026-08-14Form 42026-08-170001493152-26-038807Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Amir Shojaei 2026-08-14Form 42026-08-170001493152-26-038807Insider equity transaction reported since the proxy statement. Filing ↗
27Section 06, 2026 voteForm 8-K2026-06-220001493152-26-029486Item 5.07 · say-on-pay result. As reported: 88.29% (votes for as printed: 18,065,856). Filing ↗
28Section 06, 2025 voteForm 8-K2025-06-200001641172-25-015665Item 5.07 · say-on-pay result. As reported: 95.86% (votes for as printed: 22,496,427). Filing ↗
29Section 06, 2024 voteForm 8-K2024-06-170001493152-24-024111Item 5.07 · say-on-pay result. As reported: 89.7% (votes for as printed: 14,877,198). Filing ↗
30Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
31Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
32Section 09b board cost (computed)Computed——Cash 268,750 + equity 675,042 + all other 0 = 943,792, summed across the director compensation table rows.machine: formula: Σ = 943,792
33Harrow (subject), Section 10b CEO totalDEF 14A2026-04-240001493152-26-018912CEO total compensation as printed in Harrow's own proxy. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999
34Mirum Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001759425-26-000027CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210
35ANI Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-090001023024-26-000039CEO total compensation as printed in ANI Pharmaceuticals's own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154
36Arrowhead Pharmaceuticals, Section 10b CEO totalDEF 14A2026-01-270000879407-26-000019CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484
37Dynavax Technologies, Section 10b CEO totalDEF 14A2025-04-170000930413-25-001273CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗
38Ardelyx, Section 10b CEO totalDEF 14A2026-04-290001140361-26-017800CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121
39STAAR Surgical, Section 10b CEO totalDEF 14A2026-05-040000718937-26-000015CEO total compensation as printed in STAAR Surgical's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
40Tarsus Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001819790-26-000028CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601
41Eyepoint Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182035CEO total compensation as printed in Eyepoint Pharmaceuticals's own proxy. As printed: 5,568,352. Filing ↗machine: r2 · c22 · span 573692–573701
42Agios Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
43RxSight, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187240CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. Filing ↗
44Heron Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001193125-26-196306CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221
45Ironwood Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
46Section 10a, STAAR Surgical reciprocityDEF 14A—0000718937-26-000015STAAR Surgical's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
47Section 10a, Mirum Pharmaceuticals reciprocityDEF 14A—0001759425-26-000027Mirum Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
48Section 10a, Dynavax Technologies reciprocityDEF 14A—0000930413-25-001273Dynavax Technologies's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
49Section 10a, RxSight reciprocityDEF 14A—0001193125-26-187240RxSight's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
50Section 10a, Arrowhead Pharmaceuticals reciprocityDEF 14A—0000879407-26-000019Arrowhead Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
51Section 10a, Ardelyx reciprocityDEF 14A—0001140361-26-017800Ardelyx's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
52Section 10a, Agios Pharmaceuticals reciprocityDEF 14A—0001193125-26-177086Agios Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
53Section 10a, Ironwood Pharmaceuticals reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
54Section 10a, Heron Therapeutics reciprocityDEF 14A—0001193125-26-196306Heron Therapeutics names Harrow in its own disclosed peer group (read from its most recent proxy). Filing ↗
55Section 10a, ANI Pharmaceuticals reciprocityDEF 14A—0001023024-26-000039ANI Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Harrow. Filing ↗
56Section 10a, Tarsus Pharmaceuticals reciprocityDEF 14A—0001819790-26-000028Tarsus Pharmaceuticals names Harrow in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.